Clinical Trial Update: Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty [Phase 1]

View source ↗

Summary

Phase 1 clinical trial from Shanghai evaluates autologous CD133(+) cells as adjuvant therapy to below-the-knee percutaneous transluminal angioplasty for periphe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• Autologous CD133(+) cells (CD133-positive cells)

Snippet

Sponsor: Shanghai 10th People's Hospital | Conditions: Peripheral Arterial Disease | Phase 1 | Status: UNKNOWN